Home › Cerenis Receives EMA Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies
 

Keywords :   


Cerenis Receives EMA Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies

2014-09-03 12:18:47| drugdiscoveryonline Home Page

Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, recently announced that it has received two separate Orphan Drug Designations from the European Medicines Agency (EMA) for the use of CER-001 in the treatment of patients with rare genetic defects in HDL synthesis/maturation pathways, specifically apoA-I deficiency and ABCA1 deficiency

Tags: treatment drug receives deficiencies

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11NI rise hits workers harder than employers, says OBR
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 8
05.11Tropical Storm Rafael Public Advisory Number 8
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 8
05.11Lenzing Expands Nonwovens Range
05.11Netflix Europe offices raided in tax fraud probe
More »